Company Filing History:
5 out of 987 
4 out of 80 
2 out of 232 
Years Active: 2019-2023
Title: Innovations of Inventor Guiying Cui
Introduction
Guiying Cui is a notable inventor based in Atlanta, GA, who has made significant contributions to the field of medical research. With a total of five patents to his name, Cui's work primarily focuses on developing compounds for the management of diseases related to the cystic fibrosis transmembrane conductance regulator (CFTR) protein. His innovative approaches aim to improve treatment options for patients suffering from various respiratory and digestive conditions.
Latest Patents
Guiying Cui's latest patents include groundbreaking compounds such as 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide. This patent relates to methods of treating or preventing CFTR-mediated diseases, including cystic fibrosis and chronic obstructive pulmonary disease. The compound is designed to be administered in effective amounts to individuals in need. Another significant patent involves 2-amino-N'-benzylideneacetohydrazides and their derivatives, which also target CFTR-mediated diseases. These compounds offer potential therapeutic benefits for conditions like asthma and chronic bronchitis.
Career Highlights
Throughout his career, Guiying Cui has worked with esteemed institutions such as Emory University and Children's Healthcare of Atlanta, Inc. His research has contributed to advancements in understanding and treating CFTR-related diseases. His dedication to innovation in medical science has positioned him as a key figure in his field.
Collaborations
Guiying Cui has collaborated with notable colleagues, including Nael McCarty and Hanoch Senderowitz. These partnerships have fostered a collaborative environment that enhances research outcomes and drives innovation in medical treatments.
Conclusion
Guiying Cui's contributions to the field of medical research through his innovative patents and collaborations highlight his commitment to improving patient care. His work continues to pave the way for advancements in the treatment of CFTR-mediated diseases.